Jump to Main Contents
ncc en

Home > Information


May 29, 2023
Visit by Stella Kyriakides, European commissioner for Health and Food Safety
May 24, 2023
G7 Cancer is launched
Apr. 19, 2023
World-first confirmation of standard treatment for RAS wild-type colorectal cancer-Paper published in JAMA-
Apr. 12, 2023
Start of Clinical Research of the First Japanese-Produced Next-Generation Photon Counting Computed Tomography
Apr. 10, 2023
Efficacy of Anti-HER2 Therapy with Trastuzumab Deluxecan in Uterine Carcinosarcoma Consistent with PDX-model predictions of efficacy, paving the way for the development of treatments for rare cancers.
Apr. 3, 2023
A clinical trial of Tazemetostat for pediatric and AYA patients with malignant tumors which have no standard treatment or which is refractory to standard treatment using Patient-Proposed Healthcare Service (NCCH2214/ TURTLE trial) to improve drug access for pediatric and AYA patients with refractory tumors.
Mar. 27, 2023
President of National Cancer Center Mongolia Visit
Mar. 14, 2023
World’s Largest Gastric Cancer Genomic Study Reveals Treatment Targets for Japanese Patients Alcohol intake link gives hope for improving prevention strategies
Mar. 9, 2023
President of National Cancer Center Korea Visit
Mar. 9, 2023
French National Cancer Institute(INCa)delegation visited
Mar. 9, 2023
Franco-Japanese Immuno-Oncology Research Workshop
Feb. 28, 2023
Questionable practices identified by an examination of therapeutic plan reviews performed by certified committees under the Act on the Safety of Regenerative Medicine
Jan. 24, 2023
Clinical Utility of Circulating Tumor DNA After Surgery for Colorectal Cancer Demonstrated in a Large-Scale Prospective Study -A Step toward Personalized Postoperative Adjuvant Chemotherapy-
Jan. 5, 2023
Moonshot Research and Development Program ‘Actualization of a cancer-free society through regulation of chronic inflammation’ launched